Posted on 8/14/20

Viking Therapeutics: Another Year In Review

SummaryRecently announced Q2'20 financial results and provided key updates on development timelines.Filed IND for VK0214 in X-ALD. Expect to commence Phase 1 dosing study in healthy . . .